News & Updates
Filter by Specialty:
Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma
A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.
Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma
30 Jun 2022Poor glycaemic control tied to COVID-19 progression
High concentrations of glycated haemoglobin (HbA1c) at hospital admission appears to increase the risk of COVID-19 progression to severe disease, a recent study has found.
Poor glycaemic control tied to COVID-19 progression
30 Jun 2022Persistent ALT elevation triples risk of future T2D among overweight, obese children
Children with overweight or obesity risk developing future type 2 diabetes (T2D) by threefold in the presence of persistent elevations in alanine aminotransferases (ALT), according to a study presented at the 54th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN 2022).
Persistent ALT elevation triples risk of future T2D among overweight, obese children
30 Jun 2022Optimism helps prevent cardiovascular disease, death
Being optimistic appears to reduce the risk of all-cause mortality and of cardiovascular disease (CVD), claims a recent study.
Optimism helps prevent cardiovascular disease, death
30 Jun 2022
Antioxidant cocktail works against diabetic polyneuropathy in T2D
Treatment with a combination of succinic acid, inosine, nicotinamide, and riboflavin (SINR) is safe and alleviates the symptoms of diabetic polyneuropathy in patients with type 2 diabetes (T2D), according to data from the CYLINDER study.
